These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 10027779)
1. Peptide binding alpha1alpha2 domain of HLA-B27 contributes to the disease pathogenesis in transgenic mice. Khare SD; Lee S; Bull MJ; Hanson J; Luthra HS; Hammerling GJ; David CS Hum Immunol; 1999 Feb; 60(2):116-26. PubMed ID: 10027779 [TBL] [Abstract][Full Text] [Related]
2. Spontaneous inflammatory disease in HLA-B27 transgenic mice is independent of MHC class II molecules: a direct role for B27 heavy chains and not B27-derived peptides. Khare SD; Bull MJ; Hanson J; Luthra HS; David CS J Immunol; 1998 Jan; 160(1):101-6. PubMed ID: 9551961 [TBL] [Abstract][Full Text] [Related]
3. HLA-B27 heavy chains contribute to spontaneous inflammatory disease in B27/human beta2-microglobulin (beta2m) double transgenic mice with disrupted mouse beta2m. Khare SD; Hansen J; Luthra HS; David CS J Clin Invest; 1996 Dec; 98(12):2746-55. PubMed ID: 8981920 [TBL] [Abstract][Full Text] [Related]
4. Unraveling the mystery of HLA-B27 association with human spondyloarthropathies using transgenic and knock out mice. Khare SD; Luthra HS; David CS Semin Immunol; 1998 Feb; 10(1):15-23. PubMed ID: 9529652 [TBL] [Abstract][Full Text] [Related]
5. Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking beta 2-microglobulin: a model of human spondyloarthropathies. Khare SD; Luthra HS; David CS J Exp Med; 1995 Oct; 182(4):1153-8. PubMed ID: 7561688 [TBL] [Abstract][Full Text] [Related]
6. HLA-B27 transgenic mice are susceptible to collagen-induced arthritis: type II collagen as a potential target in human disease. Lee S; Khare SD; Griffiths MM; Luthra HS; David CS Hum Immunol; 2000 Feb; 61(2):140-7. PubMed ID: 10717806 [TBL] [Abstract][Full Text] [Related]
7. Development of spontaneous arthritis in beta2-microglobulin-deficient mice without expression of HLA-B27: association with deficiency of endogenous major histocompatibility complex class I expression. Kingsbury DJ; Mear JP; Witte DP; Taurog JD; Roopenian DC; Colbert RA Arthritis Rheum; 2000 Oct; 43(10):2290-6. PubMed ID: 11037889 [TBL] [Abstract][Full Text] [Related]
8. Specificity and frequency of primary anti-HLA cytotoxic T lymphocytes in normal and HLA-B27.2-, HLA-B27.5-, and HLA-Cw3-transgenic mice. A transgenic model for MHC xenoantigen recognition. Kievits F; Boerenkamp WJ; Lokhorst W; Ivanyi P J Immunol; 1990 Jun; 144(12):4513-9. PubMed ID: 2351823 [TBL] [Abstract][Full Text] [Related]
9. NK cells from human MHC class I (HLA-B) transgenic mice do not mediate hybrid resistance killing against parental nontransgenic cells. Kung SK; Su RC; Graham JJ; Chamberlain JW; Miller RG J Immunol; 1998 Jan; 160(2):674-80. PubMed ID: 9551902 [TBL] [Abstract][Full Text] [Related]
10. Spontaneous inflammatory disease in HLA-B27 transgenic mice does not require transporter of antigenic peptides. Khare SD; Lee S; Bull MJ; Hanson J; Luthra HS; David CS Clin Immunol; 2001 Mar; 98(3):364-9. PubMed ID: 11237560 [TBL] [Abstract][Full Text] [Related]
11. Animal models of HLA-B27-associated diseases. Breban M; Hacquard-Bouder C; Falgarone G Curr Mol Med; 2004 Feb; 4(1):31-40. PubMed ID: 15011957 [TBL] [Abstract][Full Text] [Related]
12. Recognition of chlamydial antigen by HLA-B27-restricted cytotoxic T cells in HLA-B*2705 transgenic CBA (H-2k) mice. Kuon W; Lauster R; Böttcher U; Koroknay A; Ulbrecht M; Hartmann M; Grolms M; Ugrinovic S; Braun J; Weiss EH; Sieper J Arthritis Rheum; 1997 May; 40(5):945-54. PubMed ID: 9153558 [TBL] [Abstract][Full Text] [Related]
13. Human MHC class I transgenic mice deficient for H2 class I expression facilitate identification and characterization of new HLA class I-restricted viral T cell epitopes. Cheuk E; D'Souza C; Hu N; Liu Y; Lang H; Chamberlain JW J Immunol; 2002 Nov; 169(10):5571-80. PubMed ID: 12421934 [TBL] [Abstract][Full Text] [Related]
14. Animal models of HLA-B27-associated diseases: new outcomes. Hacquard-Bouder C; Ittah M; Breban M Joint Bone Spine; 2006 Mar; 73(2):132-8. PubMed ID: 16377230 [TBL] [Abstract][Full Text] [Related]
15. Arthritis in HLA-B27 transgenic animals. Taurog JD Am J Med Sci; 1998 Oct; 316(4):250-6. PubMed ID: 9766486 [TBL] [Abstract][Full Text] [Related]
16. HLA class-I-transgenic mice as model system to study MHC-restricted antigen recognition in man. Weiss EH; Schliesser G; Botteron C; McMichael A; Riethmüller G; Kievits F; Ivanyi P; Brem G Scand J Rheumatol Suppl; 1990; 87():91-6. PubMed ID: 2259893 [TBL] [Abstract][Full Text] [Related]
17. Rat MHC-linked peptide transporter alleles strongly influence peptide binding by HLA-B27 but not B27-associated inflammatory disease. Simmons WA; Leong LY; Satumtira N; Butcher GW; Howard JC; Richardson JA; Slaughter CA; Hammer RE; Taurog JD J Immunol; 1996 Feb; 156(4):1661-7. PubMed ID: 8568273 [TBL] [Abstract][Full Text] [Related]
18. Presentation of HLA class I-derived peptides: potential involvement in allorecognition and HLA-B27-associated arthritis. Parham P Immunol Rev; 1996 Dec; 154():137-54. PubMed ID: 9034866 [TBL] [Abstract][Full Text] [Related]
19. Recognition of HLA-B27 by mouse cytotoxic T-cell clones: a transgenic mouse model. Reboul M; Frangoulis B; Rocca A; Degos L; Pla M Immunogenetics; 1991; 34(3):196-200. PubMed ID: 1894313 [TBL] [Abstract][Full Text] [Related]
20. In vitro mutagenesis of HLA-B27. Amino acid substitutions at position 67 disrupt anti-B27 monoclonal antibody binding in direct relation to the size of the substituted side chain. el-Zaatari FA; Sams KC; Taurog JD J Immunol; 1990 Feb; 144(4):1512-7. PubMed ID: 1689355 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]